UPDATE: OPKO Health (OPK) Easily Tops Q3 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
OPKO Announces Third Quarter Financial and Operating Results
November 9, 2015 4:13 PM ESTConsolidated Revenue Increased to $143.0 Million From $19.8 million for the Three Months Ended September 30, 2015, and Increased to $215.5 Million from $65.6 Million for the Nine Months Ended September 30, 2015 Closed Acquisition of Bio-Reference Laboratories on August 20, 2015 Announced Genomics Collaboration with Vanderbilt University School of Medicine 4Kscore® Blood Test to Identify Risk of Aggressive Prostate Cancer Included in the National Comprehensive Cancer Network Guidelines for Cancer Early Detection RayaldeeTM New Drug Application (NDA) Accepted by FDA; Expected PDUFA Date is March 29, 2016... More



